Premium
EMPEROR ‐Reduced: confirming sodium–glucose co‐transporter 2 inhibitors as an essential treatment for patients with heart failure with reduced ejection fraction
Author(s) -
McMurray John J.V.
Publication year - 2020
Publication title -
european journal of heart failure
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.149
H-Index - 133
eISSN - 1879-0844
pISSN - 1388-9842
DOI - 10.1002/ejhf.2006
Subject(s) - heart failure , medicine , ejection fraction , empagliflozin , hazard ratio , discontinuation , cardiology , dapagliflozin , clinical endpoint , adverse effect , clinical trial , diabetes mellitus , type 2 diabetes , endocrinology , confidence interval
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom